256376-24-6
256376-24-6
Chemical Structure
BAY 41-2272
- CAS No.: 256376-24-6
- Formula:C20H17FN6
- Molecular Weight:360.39
IUPAC Name: 5-cyclopropyl-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-amine
InChIKey: ATOAHNRJAXSBOR-UHFFFAOYSA-N
SMILES: NC1=NC(C2=NN(CC3=CC=CC=C3F)C4=NC=CC=C42)=NC=C1C5CC5
Biological Activity: BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BAY 41-2272 | 99.61% | BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BAY 41-2272 (Standard) | ≥98% | BAY 41-2272 (Standard) is the analytical standard of BAY 41-2272. This product is intended for research and analytical applications. BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.71
HY-W062836BAY 41-8543 -
Similarity Score 0.70
HY-78237Nelociguat -
Similarity Score 0.68
HY-14779RRiociguat (Standard) -
Similarity Score 0.65
HY-W021162Guanylate cyclase-IN-1 -
Similarity Score 0.65
HY-14779S3Riociguat-d3 -
Similarity Score 0.64
HY-149642hDHODH-IN-13 -
Similarity Score 0.61
HY-16774Vericiguat -
Similarity Score 0.57
HY-142697SGC agonist 1 -
Similarity Score 0.54
HY-102024A2A receptor antagonist 1 -
Explore the MedChemAI to find more analogs
References
- [1]. Makrynitsa GI, et al. Mapping of the sGC Stimulator BAY 41-2272 Binding Site on H-NOX Domain and Its Regulation by the Redox State of the Heme. Front Cell Dev Biol. 2022 Jun 17;10:925457. [Content Brief]
- [2]. Vogel J, et al. sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension. Hypertens Res. 2021 Dec;44(12):1568-1577. [Content Brief]
